2012-10-06 19:11:53 -
New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research
Global Market Direct's pharmaceuticals report, "arGEN-X BV - Product Pipeline Review - 2012" provides data on the arGEN-X BV's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, arGEN-X BV's corporate website, SEC filings, investor presentations and featured press releases, both from arGEN-X BV and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
* arGEN-X BV - Brief arGEN-X BV overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of arGEN-X BV human therapeutic division.
* Overview of pipeline therapeutics
across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of arGEN-X BV with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the arGEN-X BV's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.
Full Report Details at
-
www.fastmr.com/prod/468507_argenx_bv_product_pipeline_review_201 ..
Reasons to buy
* Evaluate arGEN-X BV's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of arGEN-X BV in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the arGEN-X BV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with arGEN-X BV.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of arGEN-X BV and identify potential opportunities in those areas.
Report Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
arGEN-X BV Snapshot
arGEN-X BV Overview
Key Information
Key Facts
arGEN-X BV - Research and Development Overview
Key Therapeutic Areas
arGEN-X BV - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
arGEN-X BV - Pipeline Products Glance
arGEN-X BV - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
arGEN-X BV - Drug Profiles
ARGX-109
Product Description
Mechanism of Action
R&D Progress
ARGX-110
Product Description
Mechanism of Action
R&D Progress
ARGX-111
Product Description
Mechanism of Action
R&D Progress
Infl-004
Product Description
Mechanism of Action
R&D Progress
Onco-003
Product Description
Mechanism of Action
R&D Progress
arGEN-X BV - Pipeline Analysis
arGEN-X BV - Pipeline Products by Therapeutic Class
arGEN-X BV - Pipeline Products By Mechanism of Action
arGEN-X BV - Recent Pipeline Updates
arGEN-X BV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
arGEN-X BV, Deals Summary
arGEN-X BV, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
arGEN-X Secures $37 Million In Series B Financing Round
arGEN-X Raises Additional $4.5 Million In Series A Financing Round
Partnerships
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody
Licensing Agreements
arGEN-X Enters Into Licensing Agreement With Biowa
arGEN-X Enters Into Licensing Agreement With Eli Lilly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
arGEN-X BV, Key Information
arGEN-X BV, Key Facts
arGEN-X BV - Pipeline by Indication, 2012
arGEN-X BV - Pipeline by Stage of Development, 2012
arGEN-X BV - Monotherapy Products in Pipeline, 2012
arGEN-X BV - Pre-Clinical, 2012
arGEN-X BV - Discovery, 2012
arGEN-X BV - Pipeline By Therapeutic Class, 2012
arGEN-X BV - Pipeline Products By Mechanism of Action, 2012
arGEN-X BV - Recent Pipeline Updates, 2012
arGEN-X BV, Other Locations
arGEN-X BV, Deals Summary
arGEN-X Secures $37 Million In Series B Financing Round
arGEN-X Raises Additional $4.5 Million In Series A Financing Round
arGEN-X Enters Into Co-Development Agreement With Shire For Therapeutic Antibody
arGEN-X Enters Into Licensing Agreement With Biowa
arGEN-X Enters Into Licensing Agreement With Eli Lilly
List of Figures
arGEN-X BV - Pipeline by Indication, 2012
arGEN-X BV - Pipeline by Stage of Development, 2012
arGEN-X BV - Monotherapy Products in Pipeline, 2012
arGEN-X BV - Pipeline By Therapeutic Class, 2012
arGEN-X BV - Pipeline Products By Mechanism of Action, 2012
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at
www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
